Teacher Retirement System of Texas Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Teacher Retirement System of Texas trimmed its stake in Regeneron by 12.2% in Q4, selling 3,451 shares and leaving it with 24,932 shares valued at about $19.24 million.
• Regeneron secured FDA approval for Otarmeni, the first gene therapy to restore hearing, and said it will provide the therapy free to eligible U.S. patients, though a recent government pricing/tariff deal and MFN commitments could pressure margins.
• The company beat Q4 estimates (EPS $11.44 vs. $10.74) with 2.5% revenue growth, raised its quarterly dividend to $0.94, has a market cap near $79.5 billion, and holds a MarketBeat consensus rating of Moderate Buy with a $825.35 target.

Teacher Retirement System of Texas decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,932 shares of the biopharmaceutical company's stock after selling 3,451 shares during the quarter. Teacher Retirement System of Texas' holdings in Regeneron Pharmaceuticals were worth $19,244,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Robeco Institutional Asset Management B.V. lifted its position in Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company's stock worth $67,969,000 after buying an additional 73,176 shares during the last quarter. PGGM Investments lifted its position in Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company's stock worth $52,057,000 after buying an additional 8,187 shares during the last quarter. Sound Shore Management Inc CT bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $64,677,000. Rakuten Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $33,121,000. Finally, Ellerson Group Inc. ADV lifted its position in Regeneron Pharmaceuticals by 49.2% in the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company's stock worth $4,556,000 after buying an additional 2,671 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $751.57 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a 50 day moving average price of $762.84 and a two-hundred day moving average price of $731.09. The company has a market capitalization of $79.46 billion, a P/E ratio of 18.08, a PEG ratio of 1.71 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the company posted $12.07 earnings per share. The business's revenue was up 2.5% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.2 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals's payout ratio is presently 9.05%.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company's stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,774 shares of company stock valued at $2,942,738. Company insiders own 7.02% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating for the company in a research report on Wednesday, April 8th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an "equal weight" rating in a research report on Friday, April 10th. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an "overweight" rating in a research report on Monday, February 2nd. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $818.00 to $801.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. Finally, Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $825.35.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.